Comparative Pharmacology
Head-to-head clinical analysis: CARDIZEM versus DYNACIRC CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIZEM versus DYNACIRC CR.
CARDIZEM vs DYNACIRC CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium influx into cardiac and vascular smooth muscle cells during depolarization by binding to L-type calcium channels. This results in coronary vasodilation, decreased myocardial oxygen demand, and negative chronotropic and inotropic effects.
Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.
Oral: 30-120 mg three to four times daily; extended-release: 120-360 mg once daily. IV: Initial 0.25 mg/kg (max 25 mg) bolus over 2 minutes, may repeat in 15 minutes (0.35 mg/kg); maintenance: 5-15 mg/hour continuous infusion.
Isradipine extended-release (DynaCirc CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 3.0-4.5 hours in healthy adults; may be prolonged to 7-9 hours in elderly, hepatic impairment, or renal impairment; clinically relevant for dosing frequency.
Terminal half-life approximately 7-8 hours; sustained due to controlled-release formulation.
Primarily hepatic metabolism with extensive first-pass effect; approximately 2-4% excreted unchanged in urine; fecal excretion accounts for about 65% of dose as metabolites; renal excretion accounts for about 35% of dose as metabolites.
Primarily hepatic metabolism with biliary excretion; 20% renal, 80% fecal.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker